Breaking: $35M Funding Boosts Field Medical’s Ventricular Tachycardia Treatment
CARDIFF-BY-THE-SEA, Californie, July 2, 2025 / Prnewswire / – Field Medical, Inc., a trailblazer in cardiac ablation technology, has secured a significant $35 million Series B financing round. This funding, co-led by Biostar Capital and Cue Growth, aims to accelerate the preparation of crucial clinical trials and expand the market for the treatment of ventricular tachycardia (VT).
Accelerating Clinical Trials and Market Expansion
The new funding will support the launch of the Veritas clinical trial, a pivotal step for the company. It will also drive the development of the FieldForce™ Ablation System, a next-generation pulsed field ablation (PFA) technology designed for transmural lesion creation. This innovative approach offers a novel solution to VT ablation, addressing a critical need in electrophysiology.
FieldForce™ Ablation System: A Game Changer
The FieldForce™ Ablation System, featuring innovative catheter design and patented Fieldbending™ technology, allows for rapid and targeted ablation. This technology is poised to redefine the treatment landscape for ventricular tachycardia, offering speed, precision, and genuine clinical progress.
“Ventricular tachycardia is one of the least penetrated segments in electrophysiology, but doctors still don’t have the necessary tools,” said Dr. Steven Mickelsen, Founder and CEO of Field Medical. “What is exciting is that ventricular tachycardia (VT) reflects the beginnings of the atrial fibrillation market (AF), with strong clinical demand not satisfied by existing technology. We are ready to seize this opportunity with our latest generation therapy, designed for speed, precision and real clinical progress, progressing towards fundamental preparation and redefining the possibilities of treatment of ventricular tachycardia for high-risk patients.”
Strategic Board Renewal
To support its accelerated growth trajectory, Field Medical has announced changes within its board of directors. The new composition includes industry veterans with extensive experience in medical technology, finance, and clinical strategy. This renewal reflects the company’s commitment to dynamic leadership and strategic preparation for upcoming challenges and opportunities.
Evergreen Context: The Future of VT Treatment
Ventricular tachycardia is a serious heart rhythm condition that can lead to sudden cardiac death if left untreated. Current treatment options are limited, making innovative solutions like Field Medical’s PFA technology particularly promising. As the demand for effective VT treatments grows, so does the potential for this breakthrough technology to transform patient care.
The FieldForce™ Ablation System is an experimental device whose use is limited by federal (or American) law for research purposes. For more information on the company’s clinical approach and technology, see the recording of the Heart Rhythm 2025 satellite symposium, “PFA in the ventricle: the future of ablation.”
Stay tuned to archyde.com for the latest updates on this groundbreaking development in cardiac ablation technology.
